Prelude Therapeutics (PRLD) Equity Ratio (2019 - 2026)

Prelude Therapeutics has disclosed Equity Ratio across 8 years of filings, most recently posting 0.5 for Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.5, down 31.13% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.5 (down 31.13% YoY), and the FY2025 annual result was 0.49, down 35.15% from the prior year.
• Equity Ratio came in at 0.5 for Q1 2026 at Prelude Therapeutics, up from 0.49 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.93 in Q2 2023 to a low of 0.49 in Q4 2025.
• The 5-year median for Equity Ratio is 0.85 (2024), against an average of 0.79.
• Across the five-year window, Equity Ratio climbed 2.73% in 2023 and plunged 35.15% in 2025, its largest moves.
• Prelude Therapeutics' Equity Ratio stood at 0.89 in 2022, then retreated by 3.66% to 0.85 in 2023, then decreased by 12.28% to 0.75 in 2024, then slumped by 35.15% to 0.49 in 2025, then increased by 3.57% to 0.5 in 2026.
• The last three Equity Ratio figures came in at 0.5 (Q1 2026), 0.49 (Q4 2025), and 0.62 (Q3 2025), per Business Quant data.